Caplacizumab for treating adults experiencing an episode of acquired thrombotic thrombocytopenic purpura: Appraisal consultation

In DRAFT guidance, NICE does not recommend the use of caplacizumab with plasma exchange and immunosuppression for treating an acute episode of acquired thrombotic thrombocytopenic purpura due to limitations in the clinical evidence and very uncertain cost-effectiveness.

National Institute for Health and Care Excellence